Sharps Technology (NASDAQ: STSS) is a medical device and pharmaceutical packaging company specializing in the development and manufacturing of innovative drug delivery systems. The Company’s product lines focus on low waste and ultra-low waste syringe technologies that incorporate both passive and active safety features. These features protect front line healthcare workers from life-threatening needle stick injuries and protect the public from needle re-use. Sharps Technology has extensive expertise in specialized prefilled syringe systems and is on track to launch this new product line in Q3 2023. The Company has a manufacturing facility in Hungary and has partnered with Nephron Pharmaceuticals to expand its manufacturing capacity in the US. Visit STSSinfo.com to learn more.
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
Sharps Technology, Inc (STSS) is a client of RedChip Companies Inc. STSS, agree to pay RedChip Companies, Inc. a $10,500 monthly cash fee, beginning in March 2022, and 35,000 of STSS Rule 144 stock for 12 months of RedChip investor awareness services. STSS also agreed to pay RedChip a one-time cash fee of fifty-thousand dollars for a 10-day national TV ad campaign aired August 2024. The CEO of RedChip owns 9,500 shares of STSS common stock.
For full disclosure, visit RedChip.com/disclosures.
